非结核分枝杆菌病患者的药物依从性

IF 1.9 Q3 INFECTIOUS DISEASES

Journal of Clinical Tuberculosis and Other Mycobacterial Diseases Pub Date : 2025-06-18 DOI:10.1016/j.jctube.2025.100544

Arthur Lemson , Fleur Dijkhuizen , Ralf Stemkens , Arjan van Laarhoven , Reinout van Crevel , Jakko van Ingen , Rob Aarnoutse , Wouter Hoefsloot

{"title":"非结核分枝杆菌病患者的药物依从性","authors":"Arthur Lemson , Fleur Dijkhuizen , Ralf Stemkens , Arjan van Laarhoven , Reinout van Crevel , Jakko van Ingen , Rob Aarnoutse , Wouter Hoefsloot","doi":"10.1016/j.jctube.2025.100544","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><div>We aimed to measure and understand medication adherence in patients with nontuberculous mycobacterial (NTM) disease.</div></div><div><h3>Methods</h3><div>We enrolled adults with NTM disease receiving antimycobacterial treatment at Radboudumc, the Netherlands. Demographics and treatment outcomes were recorded, and medication adherence was assessed repeatedly. Adherence was measured using the Proportion of Days Covered (PDC) at 6 and 12 months, calculated from pharmacy records, and the 5-item Medication Adherence Report Scale (MARS-5). The Beliefs about Medicines Questionnaire (BMQ) explored reasons for (non)adherence.</div></div><div><h3>Results</h3><div>Sixty-one participants were enrolled, with a mean age of 63.2 (±12.9) years. Forty-one (67 %) had pulmonary, and 20 (33 %) extrapulmonary NTM disease, with <em>M. avium</em> complex being the most prevalent species (n = 38; 62 %). One or more adverse effects occurred in 56/61 (92 %) participants. A favorable response was seen in 34/49 (69 %) and 25/29 (86 %) participants at 6 and 12 months, respectively. The median PDC was 100 % (IQR, 99–100 %) at both timepoints, and the MARS-5 remained 5 out of 5 throughout treatment, indicating high adherence. Participants’ beliefs about the necessity of NTM treatment, as assessed in the BMQ, consistently outweighed concerns.</div></div><div><h3>Conclusions</h3><div>Medication adherence was high throughout the first year of NTM treatment, likely due to the perceived necessity of treatment and regular follow-up at our reference clinic.</div></div>","PeriodicalId":37942,"journal":{"name":"Journal of Clinical Tuberculosis and Other Mycobacterial Diseases","volume":"40 ","pages":"Article 100544"},"PeriodicalIF":1.9000,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Medication adherence in patients with nontuberculous mycobacterial disease\",\"authors\":\"Arthur Lemson , Fleur Dijkhuizen , Ralf Stemkens , Arjan van Laarhoven , Reinout van Crevel , Jakko van Ingen , Rob Aarnoutse , Wouter Hoefsloot\",\"doi\":\"10.1016/j.jctube.2025.100544\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objectives</h3><div>We aimed to measure and understand medication adherence in patients with nontuberculous mycobacterial (NTM) disease.</div></div><div><h3>Methods</h3><div>We enrolled adults with NTM disease receiving antimycobacterial treatment at Radboudumc, the Netherlands. Demographics and treatment outcomes were recorded, and medication adherence was assessed repeatedly. Adherence was measured using the Proportion of Days Covered (PDC) at 6 and 12 months, calculated from pharmacy records, and the 5-item Medication Adherence Report Scale (MARS-5). The Beliefs about Medicines Questionnaire (BMQ) explored reasons for (non)adherence.</div></div><div><h3>Results</h3><div>Sixty-one participants were enrolled, with a mean age of 63.2 (±12.9) years. Forty-one (67 %) had pulmonary, and 20 (33 %) extrapulmonary NTM disease, with <em>M. avium</em> complex being the most prevalent species (n = 38; 62 %). One or more adverse effects occurred in 56/61 (92 %) participants. A favorable response was seen in 34/49 (69 %) and 25/29 (86 %) participants at 6 and 12 months, respectively. The median PDC was 100 % (IQR, 99–100 %) at both timepoints, and the MARS-5 remained 5 out of 5 throughout treatment, indicating high adherence. Participants’ beliefs about the necessity of NTM treatment, as assessed in the BMQ, consistently outweighed concerns.</div></div><div><h3>Conclusions</h3><div>Medication adherence was high throughout the first year of NTM treatment, likely due to the perceived necessity of treatment and regular follow-up at our reference clinic.</div></div>\",\"PeriodicalId\":37942,\"journal\":{\"name\":\"Journal of Clinical Tuberculosis and Other Mycobacterial Diseases\",\"volume\":\"40 \",\"pages\":\"Article 100544\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2025-06-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Clinical Tuberculosis and Other Mycobacterial Diseases\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S240557942500035X\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Tuberculosis and Other Mycobacterial Diseases","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S240557942500035X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

摘要

目的我们旨在测量和了解非结核分枝杆菌（NTM）疾病患者的药物依从性。方法：我们招募了在荷兰Radboudumc接受抗真菌治疗的NTM成人患者。记录人口统计数据和治疗结果，并反复评估药物依从性。根据药房记录计算6个月和12个月的覆盖天数比例（PDC）和5项药物依从性报告量表（MARS-5）来衡量依从性。对药物的信念问卷（BMQ）探讨了（不）遵守的原因。结果入组61例，平均年龄63.2（±12.9）岁。41例（67%）为肺部NTM疾病，20例（33%）为肺外NTM疾病，其中鸟分枝杆菌复群是最常见的物种(n = 38；62%)。56/61（92%）的参与者发生了一种或多种不良反应。在6个月和12个月时，分别有34/49（69%）和25/29（86%）的参与者有良好的反应。两个时间点的中位PDC均为100% (IQR, 99 - 100%)， MARS-5在整个治疗过程中保持5分，表明高依从性。正如BMQ评估的那样，参与者对NTM治疗必要性的信念始终超过了担忧。结论在NTM治疗的第一年，药物依从性很高，可能是由于我们认为治疗的必要性和在参考诊所的定期随访。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Medication adherence in patients with nontuberculous mycobacterial disease

Objectives

We aimed to measure and understand medication adherence in patients with nontuberculous mycobacterial (NTM) disease.

Methods

We enrolled adults with NTM disease receiving antimycobacterial treatment at Radboudumc, the Netherlands. Demographics and treatment outcomes were recorded, and medication adherence was assessed repeatedly. Adherence was measured using the Proportion of Days Covered (PDC) at 6 and 12 months, calculated from pharmacy records, and the 5-item Medication Adherence Report Scale (MARS-5). The Beliefs about Medicines Questionnaire (BMQ) explored reasons for (non)adherence.

Results

Sixty-one participants were enrolled, with a mean age of 63.2 (±12.9) years. Forty-one (67 %) had pulmonary, and 20 (33 %) extrapulmonary NTM disease, with M. avium complex being the most prevalent species (n = 38; 62 %). One or more adverse effects occurred in 56/61 (92 %) participants. A favorable response was seen in 34/49 (69 %) and 25/29 (86 %) participants at 6 and 12 months, respectively. The median PDC was 100 % (IQR, 99–100 %) at both timepoints, and the MARS-5 remained 5 out of 5 throughout treatment, indicating high adherence. Participants’ beliefs about the necessity of NTM treatment, as assessed in the BMQ, consistently outweighed concerns.

Conclusions

Medication adherence was high throughout the first year of NTM treatment, likely due to the perceived necessity of treatment and regular follow-up at our reference clinic.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Clinical Tuberculosis and Other Mycobacterial Diseases Medicine-Pulmonary and Respiratory Medicine

CiteScore

4.00

自引率

5.00%

发文量

审稿时长

30 weeks

期刊介绍： Journal of Clinical Tuberculosis and Mycobacterial Diseases aims to provide a forum for clinically relevant articles on all aspects of tuberculosis and other mycobacterial infections, including (but not limited to) epidemiology, clinical investigation, transmission, diagnosis, treatment, drug-resistance and public policy, and encourages the submission of clinical studies, thematic reviews and case reports. Journal of Clinical Tuberculosis and Mycobacterial Diseases is an Open Access publication.